New hope for chronic mouth condition: baricitinib trial underway
NCT ID NCT06158113
First seen Jan 23, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests whether baricitinib, a drug that calms the immune system, can help people with moderate to severe oral lichen planus—a painful, long-lasting mouth condition. Ten adults who have not responded to other treatments will take the drug for six months. Researchers will measure changes in mouth sores and quality of life, and watch for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL LICHEN PLANUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UNC Dermatology and Skin Cancer Center
Chapel Hill, North Carolina, 27516, United States
Conditions
Explore the condition pages connected to this study.